<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">neurojour</journal-id><journal-title-group><journal-title xml:lang="ru">Неврологический журнал имени Л.О. Бадаляна</journal-title><trans-title-group xml:lang="en"><trans-title>L.O. Badalyan Neurological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2686-8997</issn><issn pub-type="epub">2712-794X</issn><publisher><publisher-name>ФГАУ «НМИЦ здоровья детей» Минздрава России</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.46563/2686-8997-2023-4-4-200-207</article-id><article-id custom-type="edn" pub-id-type="custom">zklmna</article-id><article-id custom-type="elpub" pub-id-type="custom">neurojour-113</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LITERATURE REVIEWS</subject></subj-group></article-categories><title-group><article-title>Лечение сиалореи у взрослых и детей с применением ботулинического токсина типа А</article-title><trans-title-group xml:lang="en"><trans-title>Treatment of sialorrhea in adults and children using botulinum toxin type A</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8849-680X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иволгин</surname><given-names>Александр Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivolgin</surname><given-names>Aleksandr F.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7596-4072</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Авсейцева</surname><given-names>Татьяна Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Avseitseva</surname><given-names>Tatyana Y.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7269-9100</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куренков</surname><given-names>Алексей Львович</given-names></name><name name-style="western" xml:lang="en"><surname>Kurenkov</surname><given-names>Alexey L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.м.н., врач-невролог, заведующий лабораторией нервных болезней Центра детской психоневрологии ФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава России, 119991, Москва</p><p>e-mail: alkurenkov@gmail.com</p></bio><bio xml:lang="en"><p>MD, PhD, DSci., Neurologist, Head of the Laboratory of Nervous Diseases of the Center for Child Psychoneurology, National Medical Research Center for Children’s Health, Moscow, 119991, Russian Federation</p><p>e-mail: alkurenkov@gmail.com</p></bio><email xlink:type="simple">alkurenkov@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6219-3384</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Артеменко</surname><given-names>Ада Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Artemenko</surname><given-names>Ada R.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8960-721X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мазур</surname><given-names>Андрей С.</given-names></name><name name-style="western" xml:lang="en"><surname>Mazur</surname><given-names>Andrey S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр высоких медицинских технологий — Центральный военный клинический госпиталь им. А.А. Вишневского» Минобороны России</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for High Medical Technologies — A.A. Vishnevsky Central Military Clinical Hospital</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАУ «Национальный медицинский исследовательский центр здоровья детей» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр высоких медицинских технологий — Центральный военный клинический госпиталь им. А.А. Вишневского» Минобороны России</institution></aff><aff xml:lang="en"><institution>National Medical Research Center for Children’s Health</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)</institution></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Healthcare of Russian Federation</institution></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБНУ «Научный центр неврологии»</institution></aff><aff xml:lang="en"><institution>Research Center of Neurology</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>11</day><month>01</month><year>2024</year></pub-date><volume>4</volume><issue>4</issue><fpage>200</fpage><lpage>207</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Иволгин А.Ф., Авсейцева Т.Ю., Куренков А.Л., Артеменко А.Р., Мазур А.С., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Иволгин А.Ф., Авсейцева Т.Ю., Куренков А.Л., Артеменко А.Р., Мазур А.С.</copyright-holder><copyright-holder xml:lang="en">Ivolgin A.F., Avseitseva T.Y., Kurenkov A.L., Artemenko A.R., Mazur A.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.neuro-journal.ru/jour/article/view/113">https://www.neuro-journal.ru/jour/article/view/113</self-uri><abstract><p>Сиалорея является частым состоянием при различных заболеваниях, встречающихся в неврологической практике среди взрослых пациентов и детей. Избыточное накопление слюны в ротовой полости и выделение её за пределы полости рта является сложной медицинской проблемой, часто вызывает осложнения основного заболевания и требует самостоятельного лечения. Выраженное слюнотечение приводит к состояниям, значительно ограничивающим социализацию пациента, усложняет уход за ним и ложится дополнительным экономическим бременем на членов семьи пациента. Спектр лечебных стратегий, направленных на уменьшение или устранение сиалореи, весьма широк и включает в себя когнитивно-поведенческую терапию, медикаментозное лечение, инъекции ботулинического токсина и хирургическое вмешательство. В основе выбора доступного варианта лечения сиалореи — тяжесть основного заболевания, результаты оценки степени выраженности накопления слюны в ротовой полости. Лекарственная терапия, а также хирургические методы лечения часто сопровождаются нежелательными явлениями. Современным и безопасным методом лечения с наименьшим количеством побочных эффектов является введение ботулинического токсина типа А в околоушные и подчелюстные слюнные железы. Отсутствие сложностей в использовании данного метода лечения позволяет рекомендовать его в рутинной лечебной практике невролога, обученного введению ботулотоксинов. В статье представлен обзор мировой литературы за последние 20  лет, а также стандартная схема применения ботулинического токсина типа А (инкоботулотоксина) для лечения сиалореи у взрослых и детей с обоснованием применения препарата под обязательным ультразвуковым контролем и при некоторых заболеваниях под анестезией.</p><sec><title>Участие авторов</title><p>Участие авторов:Иволгин А.Ф. — концепция и дизайн, написание текста, редактирование;Авсейцева Т.Ю. — написание текста;Куренков А.Л. — концепция и дизайн, написание текста, редактирование;Артеменко А.Р. — написание текста, редактирование;Мазур А.С. — написание текста, редактирование.Все авторы — утверждение окончательного варианта статьи, ответственность за целостность всех частей статьи.</p></sec><sec><title>Конфликт интересов</title><p>Конфликт интересов. Авторы декларируют отсутствие явных и потенциальных конфликтов интересов в связи с публикацией данной статьи.</p></sec><sec><title>Финансирование</title><p>Финансирование. Исследование не имело спонсорской поддержки.</p></sec><sec><title>Поступила 23</title><p>Поступила 23.08.2023Принята к печати 30.09.2023Опубликована 28.12.2023</p></sec><sec><title> </title><p> </p></sec></abstract><trans-abstract xml:lang="en"><p>Sialorrhea is a common condition in various diseases that occur in neurological practice among adult patients and children. Excessive accumulation of saliva in the oral cavity and its release outside the oral cavity is a complex medical problem that often leads to complications of the underlying disease and requires independent treatment. Severe drooling leads to conditions that significantly limit the patient’s socialization, complicates his care, and places an additional economic burden on the patient’s family members. The range of treatment strategies aimed at reducing or eliminating sialorrhea is very wide and includes cognitive behavioral therapy, medication, botulinum toxin injections, and surgery. The choice of an available treatment option for sialorrhea is based on the severity of the underlying disease and the results of assessing the severity of saliva accumulation in the oral cavity. Drug therapy, as well as surgical treatments, are often accompanied by adverse events. A modern and safe method of treatment, with the fewest side effects, is the injection of botulinum toxin type A into the parotid and submandibular salivary glands. The absence of difficulties in using this treatment method allows it being recommended in routine medical practice by a neurologist trained in the administration of botulinum toxins. The article presents a review of the world literature over the past twenty years, as well as a standard scheme for the use of botulinum toxin type A (incobotulinumtoxinA) for the treatment of sialorrhea in adults and children, with justification for the use of the drug under mandatory ultrasound control and certain diseases under anesthesia.</p><sec><title>Contribution</title><p>Contribution:Ivolgin A.F. — concept and design of the review, writing the text, editing;Avseitseva T.Y. — writing the text;Kurenkov A.L. — concept and design of the review, writing the text, editing;Artemenko A.R. — writing the text, editing;Mazur A.S. — writing the text, editing;All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.</p></sec><sec><title>Acknowledgements</title><p>Acknowledgements. The study had no sponsorship.</p></sec><sec><title>Conflict of interest</title><p>Conflict of interest. The authors declare no conflict of interest.</p></sec><sec><title>Received</title><p>Received: August 23, 2023Accepted: September 30, 2023Published: December 28, 2023</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сиалорея</kwd><kwd>ботулинический токсин типа А</kwd><kwd>инкоботулотоксин А</kwd><kwd>инсульт</kwd><kwd>болезнь Паркинсона</kwd><kwd>детский церебральный паралич</kwd><kwd>шкалы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>sialorrhea</kwd><kwd>botulinum toxin type A</kwd><kwd>incobotulinumtoxinA</kwd><kwd>stroke</kwd><kwd>Parkinson’s disease</kwd><kwd>infantile cerebral palsy</kwd><kwd>scales</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lakraj A.A., Moghimi N., Jabbari B. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel). 2013; 5(5): 1010–31. https://doi.org/10.3390/toxins5051010</mixed-citation><mixed-citation xml:lang="en">Lakraj A.A., Moghimi N., Jabbari B. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel). 2013; 5(5): 1010–31. https://doi.org/10.3390/toxins5051010</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Andersen P.M., Abrahams S., Borasio G.D., de Carvalho M., Chio A., Van Damme P., et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. Eur. J. Neurol. 2012; 19(3): 360–75. https://doi.org/10.1111/j.1468-1331.2011.03501.x</mixed-citation><mixed-citation xml:lang="en">Andersen P.M., Abrahams S., Borasio G.D., de Carvalho M., Chio A., Van Damme P., et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. Eur. J. Neurol. 2012; 19(3): 360–75. https://doi.org/10.1111/j.1468-1331.2011.03501.x</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz-Roca J.A., Pons-Fuster E., Lopez-Jornet P.J. Effectiveness of the botulinum toxin for treating sialorrhea in patients with Parkinson’s disease: a systematic review. Clin. Med. 2019; 8(3): 317. https://doi.org/10.3390/jcm8030317</mixed-citation><mixed-citation xml:lang="en">Ruiz-Roca J.A., Pons-Fuster E., Lopez-Jornet P.J. Effectiveness of the botulinum toxin for treating sialorrhea in patients with Parkinson’s disease: a systematic review. Clin. Med. 2019; 8(3): 317. https://doi.org/10.3390/jcm8030317</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Squires N., Wills A., Rowson J. The management of drooling in adults with neurological conditions. Curr. Opin. Otolaryngol. Head Neck Surg. 2012; 20(3): 171–6. https://doi.org/10.1097/moo.0b013e32835328ec</mixed-citation><mixed-citation xml:lang="en">Squires N., Wills A., Rowson J. The management of drooling in adults with neurological conditions. Curr. Opin. Otolaryngol. Head Neck Surg. 2012; 20(3): 171–6. https://doi.org/10.1097/moo.0b013e32835328ec</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Залялова З.А. Слюнотечение после инсульта. Журнал неврологии и психиатрии им. C.C. Корсакова. 2017; 117(1): 85–9. https://doi.org/10.17116/jnevro20171171185-89 https://elibrary.ru/xxdsrz</mixed-citation><mixed-citation xml:lang="en">Zalyalova Z.A. Salivation after stroke. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2017; 117(1): 85–9. https://doi.org/10.17116/jnevro20171171185-89 https://elibrary.ru/xxdsrz (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Malek N., Lawton M.A., Grosset K.A., Bajaj N., Barker R.A., Burn D.J., et al. Autonomic dysfunction in early Parkinson’s disease: results from the United Kingdom tracking Parkinson’s study. Mov. Disord. Clin. Pract. 2016; 4(4): 509–16. https://doi.org/10.1002/mdc3.12454</mixed-citation><mixed-citation xml:lang="en">Malek N., Lawton M.A., Grosset K.A., Bajaj N., Barker R.A., Burn D.J., et al. Autonomic dysfunction in early Parkinson’s disease: results from the United Kingdom tracking Parkinson’s study. Mov. Disord. Clin. Pract. 2016; 4(4): 509–16. https://doi.org/10.1002/mdc3.12454</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez-Martin P., Rodriguez-Blazquez C., Kurtis M.M., Chaudhuri K.R. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov. Disord. 2011; 26(3): 399–406. https://doi.org/10.1002/mds.23462</mixed-citation><mixed-citation xml:lang="en">Martinez-Martin P., Rodriguez-Blazquez C., Kurtis M.M., Chaudhuri K.R. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov. Disord. 2011; 26(3): 399–406. https://doi.org/10.1002/mds.23462</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Кошкарёв М.А., Иволгин А.Ф., Литвиненко И.В., Дыскин Д.Е. Возможности лечения тяжелых двигательных нарушений при впервые установленном диагнозе болезни Паркинсона. Госпитальная медицина: наука и практика. 2020; 1(1): 17–23. https://elibrary.ru/oqefua</mixed-citation><mixed-citation xml:lang="en">Koshkarev M.A., Ivolgin A.F., Litvinenko I.V., Dyskin D.E. Possibilities of treatment of severe motor disorders with the first established diagnosis of Parkinson’s disease. Gospital’naya meditsina: nauka i praktika. 2020; 1(1): 17–23. https://elibrary.ru/oqefua (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Vandenberghe N., Vallet A.E., Petitjean T., Le Cam P., Peysson S., Guérin C., et al. Absence of airway secretion accumulation predicts tolerance of noninvasive ventilation in subjects with amyotrophic lateral sclerosis. Respir. Care. 2013; 58(9): 1424–32. https://doi.org/10.4187/respcare.02103</mixed-citation><mixed-citation xml:lang="en">Vandenberghe N., Vallet A.E., Petitjean T., Le Cam P., Peysson S., Guérin C., et al. Absence of airway secretion accumulation predicts tolerance of noninvasive ventilation in subjects with amyotrophic lateral sclerosis. Respir. Care. 2013; 58(9): 1424–32. https://doi.org/10.4187/respcare.02103</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kang Y., Chun M.H., Lee S.J. Evaluation of salivary aspiration in brain-injured patients with tracheostomy. Ann. Rehabil. Med. 2013; 37(1): 96–102. https://doi.org/10.5535/arm.2013.37.1.96</mixed-citation><mixed-citation xml:lang="en">Kang Y., Chun M.H., Lee S.J. Evaluation of salivary aspiration in brain-injured patients with tracheostomy. Ann. Rehabil. Med. 2013; 37(1): 96–102. https://doi.org/10.5535/arm.2013.37.1.96</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Fairhurst C.B., Cockerill H. Management of drooling in children. Arch. Dis. Child. Educ. Pract. Ed. 2011; 96(1): 25–30. https://doi.org/10.1136/adc.2007.129478</mixed-citation><mixed-citation xml:lang="en">Fairhurst C.B., Cockerill H. Management of drooling in children. Arch. Dis. Child. Educ. Pract. Ed. 2011; 96(1): 25–30. https://doi.org/10.1136/adc.2007.129478</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Walshe M., Smith M., Pennington L. Interventions for drooling in children with cerebral palsy. Cochrane Database Syst. Rev. 2012; 11: CD008624. https://doi.org/10.1002/14651858.CD008624.pub3</mixed-citation><mixed-citation xml:lang="en">Walshe M., Smith M., Pennington L. Interventions for drooling in children with cerebral palsy. Cochrane Database Syst. Rev. 2012; 11: CD008624. https://doi.org/10.1002/14651858.CD008624.pub3</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Speyer R., Cordier R., Kim J.H., Cocks N., Michou E., Wilkes-Gillan S. Prevalence of drooling, swallowing, and feeding problems in cerebral palsy across the lifespan: a systematic review and meta-analyses. Dev. Med. Child. Neurol. 2019; 61(11): 1249–58. https://doi.org/10.1111/dmcn.14316</mixed-citation><mixed-citation xml:lang="en">Speyer R., Cordier R., Kim J.H., Cocks N., Michou E., Wilkes-Gillan S. Prevalence of drooling, swallowing, and feeding problems in cerebral palsy across the lifespan: a systematic review and meta-analyses. Dev. Med. Child. Neurol. 2019; 61(11): 1249–58. https://doi.org/10.1111/dmcn.14316</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">McIntyre S., Goldsmith S., Webb A., Ehlinger V., Hollung S.J., McConnell K., et al. Global prevalence of cerebral palsy: A systematic analysis. Dev. Med. Child. Neurol. 2022; 64(12): 1494–506. https://doi.org/10.1111/dmcn.15346</mixed-citation><mixed-citation xml:lang="en">McIntyre S., Goldsmith S., Webb A., Ehlinger V., Hollung S.J., McConnell K., et al. Global prevalence of cerebral palsy: A systematic analysis. Dev. Med. Child. Neurol. 2022; 64(12): 1494–506. https://doi.org/10.1111/dmcn.15346</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenthal M. Life expectancy and its adjustment in cerebral palsy with severe impairment: Are we doing this right? Dev. Med. Child Neurol. 2022; 64(6): 709–14. https://doi.org/10.1111/dmcn.15120</mixed-citation><mixed-citation xml:lang="en">Rosenthal M. Life expectancy and its adjustment in cerebral palsy with severe impairment: Are we doing this right? Dev. Med. Child Neurol. 2022; 64(6): 709–14. https://doi.org/10.1111/dmcn.15120</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Parkes J., Hill N., Platt M.J., Donnelly C. Oromotor dysfunction and communication impairments in children with cerebral palsy: a register study. Dev. Med. Child Neurol. 2010; 52(12): 1113–9. https://doi.org/10.1111/j.1469-8749.2010.03765.x</mixed-citation><mixed-citation xml:lang="en">Parkes J., Hill N., Platt M.J., Donnelly C. Oromotor dysfunction and communication impairments in children with cerebral palsy: a register study. Dev. Med. Child Neurol. 2010; 52(12): 1113–9. https://doi.org/10.1111/j.1469-8749.2010.03765.x</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wright R.E., Wright F.R., Carson C.A. Videofluoroscopic assessment in children with severe cerebral palsy presenting with dysphagia. Pediatr. Radiol. 1996; 26(10): 720–2. https://doi.org/10.1007/BF01383388</mixed-citation><mixed-citation xml:lang="en">Wright R.E., Wright F.R., Carson C.A. Videofluoroscopic assessment in children with severe cerebral palsy presenting with dysphagia. Pediatr. Radiol. 1996; 26(10): 720–2. https://doi.org/10.1007/BF01383388</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sforza E., Onesimo R., Leoni C., Giorgio V., Proli F., Notaro F., et al. Drooling outcome measures in paediatric disability: a systematic review. Eur. J. Pediatr. 2022; 181(7): 2575–92. https://doi.org/10.1007/s00431-022-04460-5</mixed-citation><mixed-citation xml:lang="en">Sforza E., Onesimo R., Leoni C., Giorgio V., Proli F., Notaro F., et al. Drooling outcome measures in paediatric disability: a systematic review. Eur. J. Pediatr. 2022; 181(7): 2575–92. https://doi.org/10.1007/s00431-022-04460-5</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Nascimento D., Carmona J., Mestre T., Ferreira J.J., Guimarães I. Drooling rating scales in Parkinson’s disease: A systematic review. Parkinsonism Relat. Disord. 2021; 91: 173–80. https://doi.org/10.1016/j.parkreldis.2021.09.012</mixed-citation><mixed-citation xml:lang="en">Nascimento D., Carmona J., Mestre T., Ferreira J.J., Guimarães I. Drooling rating scales in Parkinson’s disease: A systematic review. Parkinsonism Relat. Disord. 2021; 91: 173–80. https://doi.org/10.1016/j.parkreldis.2021.09.012</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Клочкова О.А., Куренков А.Л., Каримова Х.М., Бурсагова Б.И., Намазова-Баранова Л.С., Кузенкова Л.М. и др. Сиалоррея у пациентов с детским церебральным параличом: эффективность применения ботулинотерапии. Педиатрическая фармакология. 2015; 12(4): 398–406. https://doi.org/10.15690/pf.v12i4.1420 https://elibrary.ru/umtznz</mixed-citation><mixed-citation xml:lang="en">Klochkova O.A., Kurenkov A.L., Karimova Kh.M., Bursagova B.I., Namazova-Baranova L.S., Kuzenkova L.M., et al. Drooling in patients with cerebral palsy: the effectiveness of botulinum toxin a treatment. Pediatricheskaya farmakologiya. 2015; 12(4): 398–406. https://doi.org/10.15690/pf.v12i4.1420 https://elibrary.ru/umtznz (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Куренков А.Л., Кузенкова Л.М., Черников В.В., Бурсагова Б.И., Нежельская А.А., Артеменко А.Р. Применение IncobotulinumtoxinA для лечения сиалореи у пациентов с детским церебральным параличом. Неврология, нейропсихиатрия, психосоматика. 2021; 13(4): 52–9. https://doi.org/10.14412/2074-2711-2021-4-52-59 https://elibrary.ru/xdxbts</mixed-citation><mixed-citation xml:lang="en">Kurenkov A.L., Kuzenkova L.M., Chernikov V.V., Bursagova B.I., Nezhel’skaya A.A., Artemenko A.R. IncobotulinumtoxinA in the treatment of sialorrhea in patients with infantile cerebral palsy. Nevrologiya, neyropsikhiatriya, psikhosomatika. 2021; 13(4): 52–9. https://doi.org/10.14412/2074-2711-2021-4-52-59 https://elibrary.ru/xdxbts (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Isaacson J., Patel S., Torres-Yaghi Y., Pagán F. Sialorrhea in Parkinson’s disease. Toxins (Basel). 2020; 12(11): 691. https://doi.org/10.3390/toxins12110691</mixed-citation><mixed-citation xml:lang="en">Isaacson J., Patel S., Torres-Yaghi Y., Pagán F. Sialorrhea in Parkinson’s disease. Toxins (Basel). 2020; 12(11): 691. https://doi.org/10.3390/toxins12110691</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Novak I., Morgan C., Fahey M., Finch-Edmondson M., Galea C., Hines A., et al. State of the evidence traffic lights 2019: Systematic review of interventions for preventing and treating children with cerebral palsy. Curr. Neurol. Neurosci. Rep. 2020; 20(2): 3. https://doi.org/10.1007/s11910-020-1022-z</mixed-citation><mixed-citation xml:lang="en">Novak I., Morgan C., Fahey M., Finch-Edmondson M., Galea C., Hines A., et al. State of the evidence traffic lights 2019: Systematic review of interventions for preventing and treating children with cerebral palsy. Curr. Neurol. Neurosci. Rep. 2020; 20(2): 3. https://doi.org/10.1007/s11910-020-1022-z</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">McGeachan A.J., Hobson E.V., Al-Chalabi A., Stephenson J., Chandran S., Crawley F., et al. A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2017; 18(1-2): 1–9. https://doi.org/10.1080/21678421.2016.1221433</mixed-citation><mixed-citation xml:lang="en">McGeachan A.J., Hobson E.V., Al-Chalabi A., Stephenson J., Chandran S., Crawley F., et al. A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2017; 18(1-2): 1–9. https://doi.org/10.1080/21678421.2016.1221433</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Restivo D.A., Panebianco M., Casabona A., Lanza S., Marchese-Ragona R., Patti F., et al. Botulinum toxin A for sialorrhoea associated with neurological disorders: evaluation of the relationship between effect of treatment and the number of glands treated. Toxins (Basel). 2018; 10(2): 55. https://doi.org/10.3390/toxins10020055</mixed-citation><mixed-citation xml:lang="en">Restivo D.A., Panebianco M., Casabona A., Lanza S., Marchese-Ragona R., Patti F., et al. Botulinum toxin A for sialorrhoea associated with neurological disorders: evaluation of the relationship between effect of treatment and the number of glands treated. Toxins (Basel). 2018; 10(2): 55. https://doi.org/10.3390/toxins10020055</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Banfi P., Ticozzi N., Lax A., Guidugli G.A., Nicolini A., Silani V. A review of options for treating sialorrhea in amyotrophic lateral sclerosis. Respir. Care. 2015; 60(3): 446–54. https://doi.org/10.4187/respcare.02856</mixed-citation><mixed-citation xml:lang="en">Banfi P., Ticozzi N., Lax A., Guidugli G.A., Nicolini A., Silani V. A review of options for treating sialorrhea in amyotrophic lateral sclerosis. Respir. Care. 2015; 60(3): 446–54. https://doi.org/10.4187/respcare.02856</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Pellegrini A., Lunetta C., Ferrarese C., Tremolizzo L. Sialorrhoea: how to manage a frequent complication of motor neuron disease. EMJ Neurol. 2015; 3(1): 107–13. https://doi.org/10.33590/emjneurol/10312710</mixed-citation><mixed-citation xml:lang="en">Pellegrini A., Lunetta C., Ferrarese C., Tremolizzo L. Sialorrhoea: how to manage a frequent complication of motor neuron disease. EMJ Neurol. 2015; 3(1): 107–13. https://doi.org/10.33590/emjneurol/10312710</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Lagalla G., Millevolte M., Capecci M., Provinciali L., Ceravolo M.G. Long-lasting benefits of botulinum toxin type B in Parkinson’s disease-related drooling. J. Neurol. 2009; 256(4): 563–7. https://doi.org/10.1007/s00415-009-0085-1</mixed-citation><mixed-citation xml:lang="en">Lagalla G., Millevolte M., Capecci M., Provinciali L., Ceravolo M.G. Long-lasting benefits of botulinum toxin type B in Parkinson’s disease-related drooling. J. Neurol. 2009; 256(4): 563–7. https://doi.org/10.1007/s00415-009-0085-1</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Jost W.H., Friedman A., Michel O., Oehlwein C., Slawek J., Bogucki A., et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019; 92(17): e1982–91. https://doi.org/10.1212/WNL.0000000000007368</mixed-citation><mixed-citation xml:lang="en">Jost W.H., Friedman A., Michel O., Oehlwein C., Slawek J., Bogucki A., et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019; 92(17): e1982–91. https://doi.org/10.1212/WNL.0000000000007368</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Berweck S., Bonikowski M., Kim H., Althaus M., Flatau-Baqué B., Mueller D., et al. Placebo-controlled clinical trial of incobotulinumtoxinA for sialorrhea in children: SIPEXI. Neurology. 2021; 97(14): e1425–36. https://doi.org/10.1212/WNL.0000000000012573</mixed-citation><mixed-citation xml:lang="en">Berweck S., Bonikowski M., Kim H., Althaus M., Flatau-Baqué B., Mueller D., et al. Placebo-controlled clinical trial of incobotulinumtoxinA for sialorrhea in children: SIPEXI. Neurology. 2021; 97(14): e1425–36. https://doi.org/10.1212/WNL.0000000000012573</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Jost W.H., Steffen A., Berweck S. A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients. Expert. Rev. Neurother. 2021; 21(10): 1059–68. https://doi.org/10.1080/14737175.2021.1979959</mixed-citation><mixed-citation xml:lang="en">Jost W.H., Steffen A., Berweck S. A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients. Expert. Rev. Neurother. 2021; 21(10): 1059–68. https://doi.org/10.1080/14737175.2021.1979959</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Abboud W.A., Nadel S., Hassin-Baer S., Arad A., Dobriyan A., Yahalom R. Ultrasound-guided botulinum toxin injections into the salivary glands for the treatment of drooling. Isr. Med. Assoc. J. 2019; 21(2): 116–9.</mixed-citation><mixed-citation xml:lang="en">Abboud W.A., Nadel S., Hassin-Baer S., Arad A., Dobriyan A., Yahalom R. Ultrasound-guided botulinum toxin injections into the salivary glands for the treatment of drooling. Isr. Med. Assoc. J. 2019; 21(2): 116–9.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Jost W.H. The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson’s disease. J. Neural. Transm. (Vienna). 2016; 123(1): 51–5. https://doi.org/10.1007/s00702-015-1416-2</mixed-citation><mixed-citation xml:lang="en">Jost W.H. The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson’s disease. J. Neural. Transm. (Vienna). 2016; 123(1): 51–5. https://doi.org/10.1007/s00702-015-1416-2</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Dogu O., Apaydin D., Sevim S., Talas D.U., Aral M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin. Neurol. Neurosurg. 2004; 106(2): 93–6. https://doi.org/10.1016/j.clineuro.2003.10.012</mixed-citation><mixed-citation xml:lang="en">Dogu O., Apaydin D., Sevim S., Talas D.U., Aral M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin. Neurol. Neurosurg. 2004; 106(2): 93–6. https://doi.org/10.1016/j.clineuro.2003.10.012</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Breheret R., Bizon A., Jeufroy C., Laccourreye L. Ultrasound-guided botulinum toxin injections for treatment of drooling. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2011; 128(5): 224–9. https://doi.org/10.1016/j.anorl.2010.12.010</mixed-citation><mixed-citation xml:lang="en">Breheret R., Bizon A., Jeufroy C., Laccourreye L. Ultrasound-guided botulinum toxin injections for treatment of drooling. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2011; 128(5): 224–9. https://doi.org/10.1016/j.anorl.2010.12.010</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
